MedTrace Logo

Safety and Immunogenicity of rVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrently With mRNA COVID-19 Vaccine Booster Doses

NCT06587503 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2024-09-19

No results posted yet for this study

Summary

Concurrent vaccination scheduling for key target populations in Rwanda, such as healthcare workers, may confer significant advantages in the provision of vaccine coverage to several infectious diseases. This is a phase IV vaccine trial that looks to establish if two licenced vaccines, the rVSVΔG-ZEBOV-GP vaccine for protection against Ebola virus and messenger ribonucleic acid (mRNA) COVID vaccine for protection against SARS-CoV-2 virus, given concurrently to self selected healthy adult volunteers confers an acceptable safety profile and immunogenicity response.

Conditions

Interventions

BIOLOGICAL

BioNTech - Pfizer COVID-19 vaccine

Vaccine for protection from COVID-19

BIOLOGICAL

1mL saline solution

Placebo

BIOLOGICAL

rVSV∆G-ZEBOV-GP

Vaccine for protection from Zaire Ebola virus

Sponsors & Collaborators

  • Project San Francisco

    collaborator UNKNOWN

  • Rwanda Biomedical Centre

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • University of Birmingham

    lead OTHER

Principal Investigators

  • Christopher Green, PhD · University of Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-31
Primary Completion
2024-12-31
Completion
2025-05-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06587503 on ClinicalTrials.gov